NCT07003464View on ClinicalTrials.gov

Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 15, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2028

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Zanubrutinib

160 mg (2 tablets) BID. Each 4-week period constitutes one treatment cycle.

DRUG

Obinutuzumab

1000 mg IV (Days 1, 8, 15 of Cycle 1; Day 1 thereafter).Each 4-week period constitutes one treatment cycle.

DRUG

Bendamustine

70 mg/m² (Days 1-2 per cycle) for induction only (Cycles 1-4).Each 4-week period constitutes one treatment cycle.

Trial Locations (1)

130021

The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER